Publication - The Risk Factors of Progression in Asymptomatic WM

Updated: Oct 17, 2020

Study Link is here - (Originally published in the Journal of Clinical Oncology)

We are grateful to our community of supporters in the PROMISE and PCROWD studies. In these posts, we seek to share insights with you so that you're able to gain greater understanding and use the information in your treatment decisions. Video - 1:43 Minutes

Dr. Mark Bustoros, of Dana Farber Cancer Institute, provides a brief overview of his research. He identified risk factors that lead to disease progression and the appearance of symptoms in patients diagnosed with Waldenstrom Macroglobulinemia.

The research team developed a classification system to stratify the patients into high, intermediate, or low risk groups that can help identify patients who might benefit from early treatment.

Dana-Farber Cancer Insitute logo
Harvard University School of Public Health logo
Stand Up To Cancer logo
Broad Institute logo
Johns Hopkins University logo
Mayo Clinic logo

© 2018 Dana-Farber Cancer Institute, Boston MA | United States |  Terms of Use  |   Privacy Policy